H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $13

Futu NewsDec 17 19:31 · Ratings

Morgan Stanley Maintains Foghorn Therapeutics(FHTX.US) With Hold Rating, Maintains Target Price $9

Futu NewsDec 17 09:31 · Ratings

Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development

TipRanksDec 17 08:56 · Ratings

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaDec 17 05:05

Foghorn Therapeutics Is Maintained at Buy by Jefferies

Dow JonesDec 17 03:18 · Ratings

Foghorn Therapeutics Analyst Ratings

BenzingaDec 17 03:07 · Ratings